Skip to main content

Advertisement

Springer Nature Link
Log in

The role of lymphadenectomy in high risk prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Historically, patients with high risk prostate cancer were considered poor candidates for radical prostatectomy (RP) due to the likelihood of positive pelvic lymph nodes and decreased long term survival. Although there is still no consensus on the optimal therapy for this group of patients, there is increasing evidence that surgery could play a role. Cancer specific survival (CSS) rates after RP for locally advanced disease at 10 year follow up range from 29 to 72%, depending on tumor differentiation. The role of pelvic lymph node dissection (PLND) in prostate cancer remains a controversial topic. Nonetheless, in conjunction with RRP extended PLND (ePLND) should be performed as extended lymph node dissection in lieu of standard PLND may increase staging accuracy, influence decision making with respect to adjuvant therapy and possibly impact outcome. High risk patients with organ confined prostate cancer and low volume (micro)metastatic disease may be the ones to profit most from this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385–390

    PubMed  CAS  Google Scholar 

  2. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW (2004) Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 172:1835–1839

    Article  PubMed  Google Scholar 

  3. Lerner SE, Blute ML, Zincke H (1995) Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154:1447–1452

    Article  PubMed  CAS  Google Scholar 

  4. van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397

    Article  PubMed  Google Scholar 

  5. Messing E, Manola J, Sarosdy M, Wilding G, Crawford D, Trump D (2003) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer; results at 10 years of EST 3886. J Urol 169:396

    Google Scholar 

  6. D’Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW (2000) Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. Jama 284:1280–1283

    Article  PubMed  CAS  Google Scholar 

  7. Scardino P (2005) Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3(Suppl 1):S29–S33

    PubMed  Google Scholar 

  8. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131

    Article  PubMed  Google Scholar 

  9. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499 (discussion 499)

    Article  PubMed  Google Scholar 

  10. D’Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56–61

    Article  PubMed  Google Scholar 

  11. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521–1527

    Article  PubMed  Google Scholar 

  12. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685–690

    Article  PubMed  Google Scholar 

  13. Bader P, Spahn M, Huber R, Echtle D, Frohneberg D (2004) Limited lymph node dissection in prostate cancer may miss lymph node metastasis and determines outcome of apparently pN0 prostate cancer. Eur Urol 3:16 (A 55)

    Google Scholar 

  14. Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121–125

    Article  PubMed  Google Scholar 

  15. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98:788–793

    Article  PubMed  Google Scholar 

  16. Mattei A, Fuechsel FG, Dhar NB, Warncke SH, Thalmann GN, Krause T, Studer UE (2007) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125

    Article  PubMed  Google Scholar 

  17. Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, Poulsen J (2003) Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high-risk” prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37:382–386

    Article  PubMed  Google Scholar 

  18. Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39:456–466

    Article  PubMed  CAS  Google Scholar 

  19. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166:1715–1719

    Article  PubMed  CAS  Google Scholar 

  20. Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518 (discussion 518)

    Article  PubMed  Google Scholar 

  21. Heidenreich A, Varga Z, Olbert P, Hofmann R (2001) Radical pelvic lymphadenectomy in clinically localised prostate cancer: high frequency of atypical metastasis. Eur Urol 39(suppl. 5):135 (A 530)

    Google Scholar 

  22. Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M (2004) Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 171:2268–2271

    Article  PubMed  Google Scholar 

  23. Mattei A, Fuechsel FG, Warncke S, Z’Brun S, Baermann C, Krause TM, Studer UE (2005) Advantages of preoperative imaging with Technetium-99m-nanocolloid for prostate-sentinel-lymph-node-adenectomy: accuracy and surgical detection time using presurgical imaging guidance prior to gamma-probe-detection versus gamma-probe detection alone. J Urol 173:433

    Article  Google Scholar 

  24. Gronau E, Weckermann D, Harzmann R (2005) Sentinel lymph node resection in prostate cancer patients with a PSA higher than 20 ng/ml. J Urol 173:437

    Google Scholar 

  25. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499

    Article  PubMed  Google Scholar 

  26. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686

    Article  PubMed  Google Scholar 

  27. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R (2003) The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132–137

    Article  PubMed  Google Scholar 

  28. Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158:1891–1894

    Article  PubMed  CAS  Google Scholar 

  29. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, Smith JA Jr (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145–147 (discussion 147–148)

    Article  PubMed  Google Scholar 

  30. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173:1121–1125

    Article  PubMed  Google Scholar 

  31. Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320–1324 (discussion 1324–1325)

    Article  PubMed  Google Scholar 

  32. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24:3081–3088

    Article  PubMed  CAS  Google Scholar 

  33. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M (2007) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13:1192–1197

    Article  PubMed  CAS  Google Scholar 

  34. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735–2742

    Article  PubMed  Google Scholar 

  35. Golimbu M, Morales P, Al-Askari S, Brown J (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617–620

    PubMed  CAS  Google Scholar 

  36. Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140:540–543

    PubMed  CAS  Google Scholar 

  37. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281:1591–1597

    Article  PubMed  CAS  Google Scholar 

  38. Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854

    Article  PubMed  Google Scholar 

  39. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864–870 (discussion 870–861)

    Article  PubMed  Google Scholar 

  40. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172:2252–2255

    Article  PubMed  Google Scholar 

  41. Campbell SC, Klein EA, Levin HS, Piedmonte MR (1995) Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 46:352–355

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Bern, Inselspital, Bern, Switzerland

    Fiona C. Burkhard & Urs E. Studer

Authors
  1. Fiona C. Burkhard
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Urs E. Studer
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Fiona C. Burkhard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burkhard, F.C., Studer, U.E. The role of lymphadenectomy in high risk prostate cancer. World J Urol 26, 231–236 (2008). https://doi.org/10.1007/s00345-008-0251-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-008-0251-6

Keywords

Profiles

  1. Fiona C. Burkhard View author profile